Leap Therapeutics Statistics
Total Valuation
LPTX has a market cap or net worth of $11.71 million. The enterprise value is -$6.48 million.
Important Dates
The last earnings date was Thursday, August 14, 2025, before market open.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
LPTX has 41.44 million shares outstanding. The number of shares has increased by 35.62% in one year.
| Current Share Class | 41.44M |
| Shares Outstanding | 41.44M |
| Shares Change (YoY) | +35.62% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | 0.58% |
| Owned by Institutions (%) | 22.23% |
| Float | 34.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.10 |
| P/TBV Ratio | 2.03 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.34, with a Debt / Equity ratio of 0.01.
| Current Ratio | 1.34 |
| Quick Ratio | 1.32 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4,822.62 |
Financial Efficiency
Return on equity (ROE) is -183.72% and return on invested capital (ROIC) is -108.80%.
| Return on Equity (ROE) | -183.72% |
| Return on Assets (ROA) | -77.23% |
| Return on Invested Capital (ROIC) | -108.80% |
| Return on Capital Employed (ROCE) | -1,096.62% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.27M |
| Employee Count | 52 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, LPTX has paid $585,000 in taxes.
| Income Tax | 585,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.12% in the last 52 weeks. The beta is -0.22, so LPTX's price volatility has been lower than the market average.
| Beta (5Y) | -0.22 |
| 52-Week Price Change | -90.12% |
| 50-Day Moving Average | 0.31 |
| 200-Day Moving Average | 0.98 |
| Relative Strength Index (RSI) | 44.25 |
| Average Volume (20 Days) | 1,976,509 |
Short Selling Information
The latest short interest is 1.73 million, so 4.18% of the outstanding shares have been sold short.
| Short Interest | 1.73M |
| Short Previous Month | 1.53M |
| Short % of Shares Out | 4.18% |
| Short % of Float | 5.00% |
| Short Ratio (days to cover) | 1.04 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -62.69M |
| Pretax Income | -53.37M |
| Net Income | -65.92M |
| EBITDA | -62.69M |
| EBIT | -62.69M |
| Earnings Per Share (EPS) | -$1.60 |
Full Income StatementBalance Sheet
The company has $18.13 million in cash and $39,000 in debt, giving a net cash position of $18.09 million or $0.44 per share.
| Cash & Cash Equivalents | 18.13M |
| Total Debt | 39,000 |
| Net Cash | 18.09M |
| Net Cash Per Share | $0.44 |
| Equity (Book Value) | 5.72M |
| Book Value Per Share | 0.14 |
| Working Capital | 4.84M |
Full Balance SheetCash Flow
| Operating Cash Flow | -60.08M |
| Capital Expenditures | n/a |
| Free Cash Flow | -60.08M |
| FCF Per Share | -$1.45 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
